ANB101

About AnaptysBio

AnaptysBio is a San Diego-based clinical-stage biotech focused on developing innovative antibody therapeutics for autoimmune and inflammatory diseases. The company operates a dual-strategy model, advancing a proprietary clinical pipeline while generating revenue from royalties on out-licensed assets like the PD-1 antagonist Jemperli. Its transformational plan to separate into two independent public companies by end of 2026 aims to provide investors with distinct investment theses: high-growth biopharma and stable royalty income.

Therapeutic Areas

Other Undisclosed Inflammatory Indications Drugs